(Q34321682)

1 August 2017

1 reference

title

Recent advances in carcinoid pathogenesis, diagnosis and management (English)

1 reference

1 August 2017

1 reference

R B Ganim

1

1 reference

PubMed ID

11476988

1 August 2017

J A Norton

series ordinal

2

1 reference

1 August 2017

1 December 2000

1 reference

1 August 2017

1 reference

1 August 2017

9

1 reference

1 August 2017

173-179

1 reference

1 August 2017

4

1 reference

The epidemiology of carcinoid tumours in England and Scotland

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

The classification of carcinoid tum ours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Activation of the nuclear oncogenes N-myc and c-jun in carcinoid [correction of cartinoid] tumors of transgenic mice carrying the human adenovirus type 12 E1 region gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

New molecular aspects for the diagnosis and treatment of neuroendocrine gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Genome-wide search for loss of heterozygosity in transgenic mouse tumors reveals candidate tumor suppressor genes on chromosomes 9 and 16.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Overexpression of the tumour suppressor gene p53 is not implicated in neuroendocrine tumour carcinogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Absence of overexpression of p53 protein by intestinal carcinoid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Secretion of a Chromaffin Granule Protein, Chromogranin, from the Adrenal Gland after Splanchnic Stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Tumor markers in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Carcinoid tumors: imaging procedures and interventional radiology

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Value of somatostatin receptor scintigraphy for preoperative localization of carcinoids

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Primary gastric carcinoids: a view on management

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Sonographic appearance of primary small bowel carcinoid tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Endoscopic assessment of invasion of colorectal tumors with a new high-frequency ultrasound probe

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Carcinoid tumors of the gastrointestinal tract: evaluation with endoscopic ultrasonography

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Surgical treatment of mid-gut carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Use of an isotopic somatostatin receptor probe to image gut endocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Evaluation of primary pulmonary carcinoid tumors using FDG PET

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

1 reference

7 January 2021

Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0960-7404%2801%2900007-X

7 January 2021

10.1016/S0960-7404(01)00007-X

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11476988